Mutated immunoglobulin-binding protein
US10918971B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Dec 2, 2016 |
| Grant date | Feb 16, 2021 |
| Priority date | — |
| Expiry date | Jan 15, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/825
- WIPO fieldChemical engineering
- WIPO sectorChemistry
Abstract
The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.